SAB Biotherapeutics Warrant
SABSW
16 hedge funds and large institutions have $383K invested in SAB Biotherapeutics Warrant in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
14% more funds holding
Funds holding: 14 → 16 (+2)
4.15% more ownership
Funds ownership: 0% → 4.15% (+4.1%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
56% less capital invested
Capital invested by funds: $863K → $383K (-$480K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$3.49K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$1.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$669 |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$193 |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$142 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$19.2K |
| 2 |
HF
HRT Financial
New York
|
-$2.16K |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2K |
| 5 |
Jane Street
New York
|
-$10 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $272K | +$3.49K | +29,239 | +8% |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $41K | -$19.2K | -161,300 | -20% |
|
|
RCM
3
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| $27K | -$2K | -16,765 | -30% |
|
4
Balyasny Asset Management
Chicago,
Illinois
| $18K | – | – | – |
|
5
Morgan Stanley
New York
| $9K | – | – | – |
|
|
YCM
6
Yakira Capital Management
Westport,
Connecticut
| $7K | – | – | – |
|
|
EPM
7
Equitec Proprietary Markets
Chicago,
Illinois
| $3K | – | – | – |
|
|
HF
8
HRT Financial
New York
| $1K | -$2.16K | -18,110 | -43% |
|
|
9
Jane Street
New York
| $1K | -$10 | -84 | -0.8% |
|
10
Walleye Capital
New York
| $1K | – | – | – |
|
11
Walleye Trading
New York
| $1K | – | – | – |
|
|
12
Citadel Advisors
Miami,
Florida
| $1K | +$142 | +1,194 | +6% |
|
|
FTUS
13
Flow Traders U.S.
New York
| $1K | +$1.4K | +11,739 | New |
|
|
14
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2K | -10,944 | Closed |
|
|
WAM
15
Wolverine Asset Management
Chicago,
Illinois
| – | +$193 | +1,621 | New |
|
|
16
UBS Group
Zurich,
Switzerland
| – | +$669 | +5,606 | New |
|
SABSW Hedge Fund Activity: Q3 2022 in Review
16 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q3 2022, worth a combined $383K — down 56% from $863K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SABSW positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was LMR Partners, adding an estimated $3.49K. The largest seller was Shaolin Capital Management, cutting an estimated $19.2K.
- 16 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q3 2022, up from 14 in Q2 2022.
- Funds reported $383K of SAB Biotherapeutics Warrant stock for Q3 2022, down 56% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics Warrant positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q3 2022 was LMR Partners, an estimated $3.49K added.
- The largest SAB Biotherapeutics Warrant seller in Q3 2022 was Shaolin Capital Management, an estimated $19.2K sold.
Based on aggregated 13F filings for Q3 2022.